Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | RHEB | Q15382 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876596 | 0.88 | KDM4E (0.58) | MAPTKDM4EGPBAR1CYP1A2CYP2C19 | |
| SCHEMBL876054 | 0.81 | KDM4E (1.00) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL877203 | 0.81 | MAPT (0.74) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL877302 | 0.80 | KDM4E (0.58) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL876477 | 0.80 | KDM4E (0.61) | MAPTKDM4EGPBAR1 | |
| SCHEMBL876428 | 0.80 | KDM4E (0.72) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL875983 | 0.79 | MAPT (0.75) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL15057794 | 0.78 | SMN1; SMN2 (0.67) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL876600 | 0.77 | KDM4E (0.57) | MAPTKDM4EGPBAR1LMNACYP1A2 | |
| SCHEMBL15058115 | 0.74 | GPBAR1 (0.64) | GPBAR1CYP1A2CYP2C19CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| CN-104220429-A | Non-systemic tgr5 agonists | ARDELYX INC | 2014-12-17 | — | — | CN | disclosed |
| EP-2794576-A1 | NON-SYSTEMIC TGR5 AGONISTS | Ardelyx, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096771-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | MAPT 1499/4885KDM4E 2830/4885GPBAR1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.